查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103544

經皮腎鏡取石術市場：全球市場預測，2026-2032年

Percutaneous Nephrolithotomy Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，經皮腎鏡取石術(PCNL) 市場將成長至 30.3 億美元，複合年成長率為 7.41%。

主要市場統計數據
基準年 2025 18.3億美元
預計年份：2026年 19.6億美元
預測年份：2032年 30.3億美元
複合年成長率 (%) 7.41%

經皮腎鏡取石術）是一種微創手術，透過經皮腎穿刺的小通道取出體積較大、結構複雜、呈鹿角狀或難治性腎結石。臨床指引通常建議對直徑大於2公分的腎結石或某些預期對體外震波碎石術（ESWL）或逆行性腎內手術（RIRS）無效的下腎盞結石採用PCNL，使其成為泌尿系統的基石治療方法。該手術已從標準PCNL發展到微創PCNL、超微創PCNL、無管PCNL、仰臥位PCNL和影像引導入路技術，旨在減少出血、縮短住院時間、提高結石清除率並加快患者康復。腎結石的盛行率不斷上升，這與脫水、膳食鈉攝取量過高、肥胖、METABOLIC INC.症候群、反覆尿道感染以及氣候相關的高溫暴露密切相關，持續推動著三級醫療機構和泌尿系統中心對腎結石手術的需求。此領域的發展趨勢受到多種技術的融合影響，例如內視鏡視覺化、雷射碎石、超音波和透視引導、一次性及可重複使用的腎鏡、輸液鞘套、導管導引線、放大鏡、切石器以及術後引流液等。決策者越來越關注能夠標準化臨床療效、減少併發症、提高手術室效率、確保醫保報銷、預防感染以及確保腎臟通路安全的訓練模式。

經經皮腎鏡取石術術的變革性變化

經皮腎鏡取石術（PCNL）正經歷著一場變革，其驅動力包括器械小型化、數位化成像、以患者為中心的手術全期期方案，以及對兼顧高結石清除率和低併發症發生率的技術的日益青睞。微創PCNL和採用更小穿刺通道的手術方法正變得越來越普遍。這是因為較小的穿刺通道可以降低出血風險，並有望縮短住院時間，儘管對於結石負荷較大的病例，病例選擇仍然至關重要。仰臥位因其易於麻醉、呼吸道管理簡便以及可結合順行和逆行腎鏡手術等優點，正被許多醫療機構廣泛採用。隨著醫療機構努力減少患者和手術團隊的輻射暴露，超音波引導下腎穿刺術正受到越來越多的關注。同時，由於其操作簡單、能夠即時顯示影像以及工作流程成熟，透視仍被廣泛使用。快速復健外科（ERAS）原則正在影響手術全期抗生素的合理使用、疼痛管理、早期移位以及合格的患者的無管化方案。另一個重要的轉變是基於模擬的訓練和系統性能力評估的重要性日益凸顯，因為經皮腎鏡取石術（PCNL）的療效與入路部位的準確性、結石的複雜程度、灌注管理和併發症處理密切相關。醫療機構也越來越重視醫療設備的再處理標準，在有感染風險的情況下使用一次性配件，並採用能夠確保雷射、超音波碎石器、吸引輔助系統和高解析度內視鏡平台穩定供應的採購模式。

人工智慧對經皮腎鏡取石術的累積影響

人工智慧 (AI) 正開始影響整個經皮腎鏡取石術 (PCNL) 生態系統，包括診斷、手術計劃、影像輔助、工作流程最佳化和術後風險分層。 AI 驅動的影像分析可以輔助腎盂系統的解剖定位，從而幫助檢測腎結石、評估結石體積、透過電腦斷層掃描 (CT) 進行密度表徵以及規劃手術入路。目前正在研究機器學習模型，透過整合結石負荷、腎積水、腎臟解剖結構、尿液培養觀察、既往手術史和合併症等變量，來預測是否需要取石、腎臟病風險、手術時間以及進行其他手術的可行性。雖然術中應用仍在發展中，但 AI 驅動的分割、放大影像引導和決策支援工具有望標準化腎臟入路方法並減少術者間的差異。此外，利用自然語言處理技術可以從臨床記錄中提取手術詳情、併發症、結石成分和追蹤結果，從而提高註冊資料收集的準確性。人工智慧的整體影響並非在於取代外科手術專家，而是提高手術的準確性、一致性、記錄保存和運作效率。人工智慧的實施取決於檢驗的臨床表現、透明的演算法、與影像和電子健康記錄系統的整合、網路安全措施以及監管合規性。將人工智慧工具與多學科管治、泌尿系統監督和可衡量的品質指標相結合的醫療機構，最能將數位創新轉化為更安全、更有效率的經皮腎鏡取石術石術。

經皮腎鏡取石術的關鍵區域性見解

在亞太地區，由於人口眾多的國家腎結石高發生、三級醫療體系的擴張以及內視鏡泌尿系統培訓的日益普及，經皮腎鏡取石術（PCNL）的臨床意義日益凸顯。中國、印度、日本、韓國和澳洲的PCNL應用模式各不相同。在發達的都市區，小型化器械、雷射系統和聯合內視鏡手術的應用日益增多；而在遍遠地區，醫療資源的匱乏仍然影響著相關文獻的發表。北美地區的特點是：以指南為基礎的成熟泌尿系統實踐、廣泛的斷層掃描成像技術應用、完善的門診和住院手術基礎設施，以及對結石清除率、降低再入院率、減少輻射暴露和感染控制等品質指標的重視。在拉丁美洲，由專家主導的內視鏡泌尿系統計畫、大都會醫院雷射和成像平台的日益普及以及復發性結石的需求都在不斷成長。然而，保險報銷的差異以及技術取得的便利性可能會影響手術時機和器械的選擇。在歐洲，臨床指南的全面實施、多中心合作研究的文化以及微創泌尿系統技術的廣泛應用取得了成功，促使人們更加關注減少輻射暴露、合理使用抗生素以及某些結石治療的門診手術可行性。在中東，由於氣候乾旱、脫水風險和飲食因素，患者面臨嚴重的腎結石負擔，經皮腎鏡取石術（PCNL）已成為先進醫院的重要治療選擇，尤其是在複雜結石和復發性疾病較常見的地區。非洲的情況則更為複雜，PCNL主要集中在大型出版機構和私立醫院，而更廣泛的普及則取決於影像設備、訓練有素的泌尿系統、手術室資源以及耗材的可負擔性。在所有地區，最主要的通用促進因素是結石複雜性的增加、病人對微創治療的需求、專科醫師培訓以及醫院對提高泌尿系統能力的投入。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體洞察

在東協，經皮腎鏡取石術（PCNL）框架正透過改善都市區三級醫療機構的可及性、加強區域間培訓合作以及推廣內視鏡泌尿系統設備而得到擴展；然而，大都會圈和農村醫療環境在可及性方面仍然存在差距。海灣合作理事會（GCC）地區在腎結石治療方面佔據關鍵地位，這得益於其高溫氣候、脫水風險以及與生活方式相關的代謝風險因素，這些因素均會導致結石復發。該地區資金充足的醫院網路已實施了先進的影像技術、雷射碎石術和微創泌尿系統治療方案。歐盟透過協調醫療設備法規、積極推廣指南、開展跨境調查以及重點關注輻射防護和合理使用抗生素等措施，支持PCNL的實踐，從而促進複雜結石的標準化治療。金磚國家（BRICS）是一個多元化的群體，擁有龐大的病患群體和不斷發展的專科醫療體系。中國和印度在手術量、培訓需求和成本效益高的創新方面尤其重要，而巴西、俄羅斯和南非則在技術應用方面取得了進展，主要體現在先進的醫院和學術機構中。七國集團（G7）國家的特點是外科基礎設施成熟、擁有先進的影像技術、完善的醫保報銷體系、臨床品質高、基於實證醫學的患者選擇標準，並且高度重視技術評估。北約成員國與北美和歐洲有顯著重疊，這些地區的國防和公共衛生體係可能會影響採購系統的穩健性、醫療設備的標準化程度、對數位外科工具網路安全的預期以及高級手術護理的訓練能力。在這一集團國家中，經皮腎鏡取石術（PCNL）的普及並非受單一經濟因素的影響，而是受到多種因素相互作用的影響，例如對臨床指南的遵循、醫療專業人員的專業水平、醫療設備的可及性、保險報銷以及複雜腎結石疾病的負擔。

各國經皮腎鏡取石術的關鍵訊息

在美國，經皮腎鏡取石術（PCNL）的應用已相當成熟，這得益於以指南為基礎的醫學實踐、先進的影像技術、高度專業化的手術流程，以及對降低輻射暴露和提高複雜結石患者住院效率的日益重視。加拿大也擁有類似的實證臨床框架，但其可及性取決於各州醫療系統的容量、專科醫生的分佈以及非緊急結石手術的等待時間管理。在墨西哥和巴西，PCNL 被視為複雜結石的主要治療方法，都市區醫療機構的內視鏡泌尿系統能力也不斷提升。在這些國家，科技的可近性、保險報銷以及區域可近性決定了病患的治療途徑。在英國，重點在於標準化的泌尿系統泌尿系統已十分普及，這得益於先進的醫院基礎設施、臨床培訓以及醫療設備的品質標準。在義大利和西班牙，內視鏡泌尿系統已相當成熟，人們對微創經皮腎鏡取石術（mini-PCNL）、無管技術以及針對合適患者的手術全期最佳化越來越感興趣。在俄羅斯，主要都市區和大學醫院均具備經皮腎鏡取石術的能力，區域投資和專科培訓正在塑造轉診模式。在中國，由於患者數量龐大、醫院基礎設施不斷完善以及內視鏡泌尿系統技術水平的提高，該手術的重要性極高。同時，在印度，腎結石是一個沉重的負擔，公立和私立醫療機構都對經濟有效的經皮腎鏡取石解決方案有著廣泛的需求。日本和韓國的特點是擁有先進的成像技術、高技術標準以及精密的內視鏡技術，並將病患安全和手術精準性置於臨床實踐的核心。在澳大利亞，現代化的泌尿系統基礎設施與區域性醫療服務可及性挑戰並存，轉診網路和專科醫生的配備對於複雜腎結石的治療至關重要。在這些國家，對經皮腎鏡取石術 (PCNL) 的需求受到復發性腎結石、結石複雜性、基於指南的適應症選擇以及在降低再次治療和併發症的同時保留腎功能的臨床需求所驅動。

為行業領導者提供的實用建議

產業領導者應優先考慮經臨床驗證的創新技術，這些技術能夠提高結石清除率、減少併發症，並無縫融入泌尿系統的工作流程。醫療設備和技術策略應著重於小型化通路系統、高畫質視覺化技術、高效率的切開取石平台、吸石輔助結石清除技術、減少輻射暴露的影像解決方案，以及符合泌尿系統設計、有助於提高手術操作一致性的器材。醫院和採購團隊應評估整體價值，不僅要考慮產品成本，還要考慮手術時間、一次性耗材、消毒負擔、感染控制、訓練需求以及降低再入院率等因素。泌尿外科應透過模擬訓練、引導式通路方案、多學科併發症評估以及標準化報告（包括結石清除情況、出血、發燒、膿毒症、輸血、住院時間和輔助手術等結果）來加強經皮腎鏡取石術（PCNL）的培訓。臨床領導者也應使抗生素方案與基於培養的治療和合理使用抗生素（AMS）政策保持一致，尤其考慮到PCNL術後可能發生嚴重的感染疾病併發症。在數位轉型計畫中，人工智慧和分析技術只有在經過當地患者群體檢驗後才能採用，確保其可解釋性、網路安全性、互通性和臨床醫生監督。部署過程中，相關人員應根據當地實際情況調整解決方案。具體而言，應為先進的醫療中心提供高品質的整合平台，為資源匱乏的環境提供耐用且經濟高效的系統，並在勞動力短缺成為主要瓶頸的地區實施以教育主導的模式。

調查方法

本執行摘要採用結構化的二手調查方法撰寫，重點關注與經皮腎鏡取石術和腎結石治療相關的檢驗且有數據支持的資訊來源。該方法強調同行評審的臨床文獻、泌尿系統協會指南、監管資訊、公共衛生資源、醫院實踐標準以及已發表的關於手術流程、併發症、影像學、人工智慧和當地醫療基礎設施的證據。關鍵主題透過「三角驗證」法進行評估，該方法交叉引用了臨床共識聲明、系統綜述、關於腎結石風險因素的流行病學證據以及關於微創泌尿系統治療應用趨勢的文獻。特別注意避免未經證實的數字聲明、推測性預測和檢驗的商業性聲明。利用可觀察的醫療保健系統特徵、疾病負擔因素、氣候和生活方式相關的風險因素、技術可及性、專家資源以及指南實施模式，整合了區域、群體和國家層面的見解。本調查方法不包括市場規模估算、市場佔有率計算和預測。相反，它側重於定性證據、臨床相關性、戰略意義以及從參與經皮腎鏡取石術術 (PCNL) 設備、服務、培訓和醫療保健服務的相關人員那裡收集的可操作見解。

結論

經皮腎鏡取石術，在治療大型和難治性腎結石方面已確立了重要地位。該領域正透過器械小型化、影像引導技術的改進、患者篩選標準的最佳化、基於模擬的培訓、促進康復的方案以及新興的人工智慧決策支援系統而不斷發展。儘管各地醫療基礎設施、專家資源、保險報銷、技術獲取以及腎結石風險模式有所不同，但其全球發展方向是一致的：更安全的手術操作、更高的手術效率、更低的併發症發生率以及更完善的治療效果評估。將具有臨床意義的創新與教育、工作流程整合、可負擔性和循證醫學相結合的行業相關人員，預計將在支持泌尿系統和醫療保健系統方面佔據更有利的地位。 PCNL 的下一階段發展取決於檢驗的技術、標準化的品質標準以及複雜腎結石患者公平地獲得先進的內視鏡泌尿系統治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：經皮腎鏡取石術市場：依產品類型分類

  • 腎鏡
  • 擴充系統
  • 穿刺針
  • 導管導引線
  • 鞘套和接入系統
  • 取石器械
  • 破碎系統

第8章：經皮腎鏡取石術市場：依手術類型分類

  • 微
  • 小型的
  • 標準
  • 超迷你

第9章：經皮腎鏡取石術市場：依結石類型分類

  • 草酸鈣結石
  • 尿酸結石
  • 鳥糞石
  • 胱氨酸結石

第10章：經皮腎鏡取石術市場：依結石大小分類

  • 10毫米或更小
  • 10～20mm
  • 超過20毫米

第11章：經皮腎鏡取石術市場：依最終用戶分類

  • 醫院
  • 門診手術中心（ASC）
  • 泌尿系統診所
  • 腎結石治療中心
  • 學術研究機構

第12章：經皮腎鏡取石術市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：經皮腎鏡取石術市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章經皮腎鏡取石術市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Applaud Medical, Inc.
  • Bard Medical Division
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Coloplast A/S
  • Cook Medical LLC
  • DirexGroup
  • Dornier MedTech GmbH
  • Eagle Medical Systems
  • Elmed Medical Systems
  • EMS Electro Medical Systems SA
  • Inceler Medikal Co. Ltd.
  • KARL STORZ SE & Co. KG
  • Maxer Endoscopy GmbH
  • Medispec Ltd.
  • Olympus Corporation
  • Optimed Medizinische Instrumente GmbH
  • Quanta System SpA
  • Richard Wolf GmbH
  • Rocamed SAM
  • Shenzhen Huikang Medical Apparatus Co., Ltd.
  • Siemens Healthineers AG
  • Teleflex Incorporated
  • Urotech GmbH
  • Well Lead Medical Co., Ltd.
Product Code: MRR-C002B1C99560

The Percutaneous Nephrolithotomy Market is projected to grow by USD 3.03 billion at a CAGR of 7.41% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.83 billion
Estimated Year [2026] USD 1.96 billion
Forecast Year [2032] USD 3.03 billion
CAGR (%) 7.41%

Percutaneous nephrolithotomy (PCNL) is a minimally invasive surgical procedure used to remove large, complex, staghorn, or treatment-resistant kidney stones through a small percutaneous renal access tract. It remains a cornerstone intervention in urology because clinical guidelines commonly recommend PCNL for renal stones larger than 2 cm and for selected lower-pole stones where shock wave lithotripsy or retrograde intrarenal surgery may be less effective. The procedure has evolved from standard PCNL toward mini-PCNL, ultra-mini PCNL, tubeless PCNL, supine PCNL, and image-guided access techniques designed to reduce bleeding, shorten hospital stays, improve stone-free outcomes, and enhance patient recovery. Rising kidney stone disease prevalence, linked to dehydration, dietary sodium, obesity, metabolic syndrome, recurrent urinary tract infection, and climate-related heat exposure, continues to support procedural demand across tertiary hospitals and specialized urology centers. The executive landscape is shaped by a convergence of endoscopic visualization, laser lithotripsy, ultrasound and fluoroscopy guidance, single-use and reusable nephroscopes, access sheaths, guidewires, dilators, lithotripters, and postoperative drainage solutions. Decision-makers are increasingly focused on clinical effectiveness, complication reduction, operating room efficiency, reimbursement alignment, infection prevention, and training models that standardize safe renal access.

Transformative Shifts in the Percutaneous Nephrolithotomy Landscape

The PCNL landscape is undergoing transformative shifts driven by miniaturization, digital imaging, patient-centered perioperative pathways, and the growing preference for procedures that balance high stone-clearance performance with lower morbidity. Mini-PCNL and smaller tract approaches have gained adoption because reduced tract size is associated with lower bleeding risk and potentially shorter hospitalization, although case selection remains essential for large stone burdens. Supine positioning has expanded in many centers due to anesthetic access, easier airway management, and the potential for combined antegrade and retrograde intrarenal surgery. Ultrasound-guided renal puncture is receiving increased attention as institutions seek to reduce radiation exposure for patients and operating teams, while fluoroscopy remains widely used because of familiarity, real-time visualization, and established workflow. Enhanced recovery principles are influencing perioperative antibiotic stewardship, pain control, early mobilization, and tubeless protocols for suitable patients. Another significant shift is the rising importance of simulation-based training and structured competency assessment, as PCNL outcomes are closely linked to access accuracy, stone complexity, irrigation control, and complication management. Health systems are also emphasizing device reprocessing standards, disposable accessory use where infection risk is a concern, and procurement models that support consistent availability of lasers, ultrasonic lithotripsy, suction-assisted systems, and high-definition endoscopic platforms.

Cumulative Impact of Artificial Intelligence on PCNL

Artificial intelligence is beginning to influence the PCNL ecosystem across diagnosis, surgical planning, imaging support, workflow optimization, and postoperative risk stratification. AI-enabled image analysis can support kidney stone detection, stone volume assessment, density characterization on computed tomography, and anatomical mapping of calyceal systems to inform access planning. Machine learning models are being studied for predicting stone-free status, bleeding risk, sepsis risk, operative time, and likelihood of ancillary procedures by integrating variables such as stone burden, hydronephrosis, renal anatomy, urine culture findings, prior interventions, and comorbidity profiles. Intraoperative applications remain emergent, but AI-assisted segmentation, augmented image guidance, and decision-support tools may help standardize renal access and reduce variability among operators. Natural language processing can also improve registry data capture by extracting procedure details, complications, stone composition, and follow-up outcomes from clinical notes. The cumulative impact of AI is not replacement of surgical expertise but enhancement of precision, consistency, documentation, and operational efficiency. Adoption will depend on validated clinical performance, transparent algorithms, integration with imaging and electronic health record systems, cybersecurity safeguards, and regulatory compliance. Institutions that align AI tools with multidisciplinary governance, urologist oversight, and measurable quality indicators are best positioned to translate digital innovation into safer and more efficient PCNL care.

Key Regional Insights for Percutaneous Nephrolithotomy

Asia-Pacific is experiencing strong procedural relevance for PCNL due to high kidney stone burden in populous countries, expanding tertiary care capacity, and growing adoption of endourology training. China, India, Japan, South Korea, and Australia show different adoption patterns: advanced urban centers increasingly use miniaturized instruments, laser systems, and combined endoscopic approaches, while access constraints in rural areas continue to shape referral pathways. North America is characterized by mature guideline-based urology practice, high use of cross-sectional imaging, established ambulatory and inpatient surgical infrastructure, and emphasis on quality metrics such as stone-free rates, readmission reduction, radiation minimization, and infection control. Latin America is advancing through specialist-led endourology programs, growing availability of laser and imaging platforms in metropolitan hospitals, and demand linked to recurrent stone disease; however, uneven reimbursement and technology access can influence procedure timing and device selection. Europe benefits from strong clinical guideline adoption, multicenter research culture, and broad use of minimally invasive urological techniques, with increasing attention to radiation reduction, antimicrobial stewardship, and day-case feasibility for selected stone procedures. The Middle East faces a clinically significant kidney stone burden associated with arid climate, dehydration risk, and dietary factors, making PCNL an important intervention in advanced hospitals, particularly where complex stones and recurrent disease are common. Africa presents a more heterogeneous picture, with PCNL concentrated in major referral centers and private hospitals, while wider access is influenced by imaging availability, trained endourologists, operating room resources, and affordability of consumables. Across all regions, the strongest common drivers are rising stone complexity, patient demand for less invasive care, specialist training, and hospital investment in endoscopic urology capabilities.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are expanding PCNL capabilities through urban tertiary hospitals, regional training collaborations, and rising availability of endoscopic urology equipment, although access remains variable between metropolitan and provincial care settings. The GCC has a high relevance for kidney stone management because hot climate, dehydration exposure, and lifestyle-related metabolic risk factors contribute to recurrent stone disease; well-funded hospital networks in the region are adopting advanced imaging, laser lithotripsy, and minimally invasive urology pathways. The European Union supports PCNL practice through harmonized medical device regulation, strong guideline dissemination, cross-border research, and an emphasis on radiation protection and antimicrobial stewardship, encouraging standardized care pathways for complex stones. BRICS countries represent a diverse group with large patient populations and expanding specialist care; China and India are particularly important for procedural volume, training demand, and cost-sensitive innovation, while Brazil, Russia, and South Africa show adoption concentrated around advanced hospitals and academic centers. The G7 group is marked by mature surgical infrastructure, advanced imaging access, reimbursement mechanisms, and high focus on clinical quality, evidence-based patient selection, and technology assessment. NATO member countries overlap significantly with North America and Europe, where defense and public health systems can influence procurement resilience, device standardization, cybersecurity expectations for digital surgical tools, and training capacity for advanced procedural care. Across these groups, PCNL adoption is shaped less by a single economic profile and more by the intersection of guideline adherence, workforce expertise, device availability, reimbursement, and the burden of complex kidney stone disease.

Key Country Insights for Percutaneous Nephrolithotomy

The United States demonstrates mature PCNL utilization supported by guideline-driven care, advanced imaging, high procedural specialization, and increasing focus on radiation reduction and same-admission efficiency for complex stone cases. Canada shares a similar evidence-based clinical framework, with access influenced by provincial health system capacity, specialist distribution, and wait-time management for nonemergency stone surgery. Mexico and Brazil continue to expand endourology capabilities in urban referral centers, with PCNL serving as a key treatment for complex stones where technology availability, reimbursement, and regional access shape patient pathways. The United Kingdom emphasizes standardized urology guidance, public health system efficiency, and careful patient prioritization, while Germany and France show strong adoption of minimally invasive urology supported by advanced hospital infrastructure, clinical training, and device quality standards. Italy and Spain demonstrate established endourology practice, with increasing interest in mini-PCNL, tubeless approaches, and perioperative optimization for suitable patients. Russia maintains PCNL capacity in major urban and academic hospitals, with access patterns shaped by geography, regional investment, and specialist training. China has substantial procedural relevance due to its large patient base, expanding hospital infrastructure, and growing endourology expertise, while India faces high kidney stone burden and broad demand for cost-effective PCNL solutions across both public and private care settings. Japan and South Korea are characterized by sophisticated imaging, high technical standards, and adoption of advanced endoscopic approaches, with patient safety and procedural precision central to clinical practice. Australia combines modern urology infrastructure with regional access challenges, making referral networks and specialist distribution important for complex stone care. Across these countries, PCNL demand is reinforced by recurrent nephrolithiasis, stone complexity, guideline-based selection, and the clinical need to preserve renal function while reducing retreatment and complication risks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated innovation that improves stone clearance, reduces complications, and integrates smoothly into urology workflows. Device and technology strategies should focus on miniaturized access systems, high-definition visualization, efficient lithotripsy platforms, suction-assisted stone evacuation, radiation-reducing imaging solutions, and ergonomic instruments that support procedural consistency. Hospitals and procurement teams should evaluate total value rather than product cost alone, considering operating time, disposables, sterilization burden, infection control, training requirements, and readmission reduction. Urology departments should strengthen PCNL training through simulation, mentored access protocols, multidisciplinary complication review, and standardized reporting of outcomes such as stone-free status, bleeding, fever, sepsis, transfusion, length of stay, and ancillary procedures. Clinical leaders should also align antibiotic protocols with culture-directed therapy and antimicrobial stewardship, particularly because infectious complications after PCNL can be serious. Digital transformation programs should adopt AI and analytics only after validation against local patient populations and should ensure explainability, cybersecurity, interoperability, and clinician oversight. For expansion, stakeholders should tailor solutions to regional realities: premium integrated platforms for advanced centers, durable and cost-efficient systems for resource-constrained settings, and education-led models where workforce capacity is the key bottleneck.

Research Methodology

This executive summary is developed through a structured secondary research methodology focused on verified and data-backed sources relevant to percutaneous nephrolithotomy and kidney stone management. The approach emphasizes peer-reviewed clinical literature, urology association guidelines, regulatory information, public health resources, hospital practice standards, and published evidence on procedural techniques, complications, imaging, artificial intelligence, and regional healthcare infrastructure. Key themes were evaluated through triangulation across clinical consensus statements, systematic reviews, epidemiological evidence on nephrolithiasis risk factors, and documented adoption trends in minimally invasive urology. Particular attention was given to avoiding unsupported numerical claims, speculative projections, and unverified commercial assertions. Regional, group, and country-level insights were synthesized using observable healthcare system characteristics, disease burden drivers, climate and lifestyle risk factors, technology access, specialist availability, and guideline implementation patterns. The methodology excludes market sizing, market share calculation, and forecasting, focusing instead on qualitative evidence, clinical relevance, strategic implications, and actionable intelligence for stakeholders involved in PCNL devices, services, training, and care delivery.

Conclusion

Percutaneous nephrolithotomy remains an essential procedure for complex renal stone management, supported by its established role in treating large and challenging kidney stones. The field is advancing through miniaturized instruments, improved imaging guidance, refined patient selection, simulation-based training, enhanced recovery protocols, and emerging AI-enabled decision support. Regional adoption varies according to healthcare infrastructure, specialist availability, reimbursement, technology access, and kidney stone risk patterns, but the global direction is consistent: safer access, higher procedural efficiency, lower morbidity, and stronger outcome measurement. Industry participants that combine clinically meaningful innovation with education, workflow integration, affordability, and evidence generation will be better positioned to support urologists and healthcare systems. The next phase of PCNL development will depend on validated technologies, standardized quality benchmarks, and equitable access to advanced endourology care for patients with complex nephrolithiasis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Percutaneous Nephrolithotomy Market, by Product Type

  • 7.1. Introduction
  • 7.2. Nephroscopes
  • 7.3. Dilation Systems
  • 7.4. Access Needles
  • 7.5. Guidewires
  • 7.6. Sheaths & Access Systems
  • 7.7. Stone Retrieval Devices
  • 7.8. Lithotripsy Systems

8. Percutaneous Nephrolithotomy Market, by Procedure Type

  • 8.1. Introduction
  • 8.2. Micro
  • 8.3. Mini
  • 8.4. Standard
  • 8.5. Ultra Mini

9. Percutaneous Nephrolithotomy Market, by Stone Type

  • 9.1. Introduction
  • 9.2. Calcium Oxalate Stones
  • 9.3. Uric Acid Stones
  • 9.4. Struvite Stones
  • 9.5. Cystine Stones

10. Percutaneous Nephrolithotomy Market, by Stone Size

  • 10.1. Introduction
  • 10.2. Less than 10 mm
  • 10.3. 10-20 mm
  • 10.4. More Than 20 nm

11. Percutaneous Nephrolithotomy Market, by End User

  • 11.1. Introduction
  • 11.2. Hospitals
  • 11.3. Ambulatory Surgical Centers (ASCs)
  • 11.4. Specialty Urology Clinics
  • 11.5. Kidney Stone Treatment Centers
  • 11.6. Academic & Research Institutes

12. Percutaneous Nephrolithotomy Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Percutaneous Nephrolithotomy Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Percutaneous Nephrolithotomy Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Applaud Medical, Inc.
  • 16.2. Bard Medical Division
  • 16.3. Becton, Dickinson and Company
  • 16.4. Boston Scientific Corporation
  • 16.5. Coloplast A/S
  • 16.6. Cook Medical LLC
  • 16.7. DirexGroup
  • 16.8. Dornier MedTech GmbH
  • 16.9. Eagle Medical Systems
  • 16.10. Elmed Medical Systems
  • 16.11. EMS Electro Medical Systems S.A.
  • 16.12. Inceler Medikal Co. Ltd.
  • 16.13. KARL STORZ SE & Co. KG
  • 16.14. Maxer Endoscopy GmbH
  • 16.15. Medispec Ltd.
  • 16.16. Olympus Corporation
  • 16.17. Optimed Medizinische Instrumente GmbH
  • 16.18. Quanta System S.p.A.
  • 16.19. Richard Wolf GmbH
  • 16.20. Rocamed SAM
  • 16.21. Shenzhen Huikang Medical Apparatus Co., Ltd.
  • 16.22. Siemens Healthineers AG
  • 16.23. Teleflex Incorporated
  • 16.24. Urotech GmbH
  • 16.25. Well Lead Medical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEPHROSCOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEPHROSCOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEPHROSCOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DILATION SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DILATION SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DILATION SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACCESS NEEDLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACCESS NEEDLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACCESS NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GUIDEWIRES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GUIDEWIRES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GUIDEWIRES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SHEATHS & ACCESS SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHEATHS & ACCESS SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SHEATHS & ACCESS SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STONE RETRIEVAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STONE RETRIEVAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STONE RETRIEVAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LITHOTRIPSY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LITHOTRIPSY SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LITHOTRIPSY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MICRO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MICRO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICRO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MINI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STANDARD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STANDARD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STANDARD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ULTRA MINI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ULTRA MINI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ULTRA MINI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CALCIUM OXALATE STONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CALCIUM OXALATE STONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CALCIUM OXALATE STONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL URIC ACID STONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL URIC ACID STONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL URIC ACID STONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STRUVITE STONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STRUVITE STONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STRUVITE STONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYSTINE STONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYSTINE STONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CYSTINE STONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LESS THAN 10 MM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LESS THAN 10 MM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LESS THAN 10 MM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL 10-20 MM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL 10-20 MM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL 10-20 MM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MORE THAN 20 NM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MORE THAN 20 NM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MORE THAN 20 NM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMBULATORY SURGICAL CENTERS (ASCS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AMBULATORY SURGICAL CENTERS (ASCS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AMBULATORY SURGICAL CENTERS (ASCS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SPECIALTY UROLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SPECIALTY UROLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY UROLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL KIDNEY STONE TREATMENT CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL KIDNEY STONE TREATMENT CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL KIDNEY STONE TREATMENT CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. NATO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. NATO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NATO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NATO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NATO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. NATO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. G7 PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. G7 PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GCC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. JAPAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. JAPAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. JAPAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. JAPAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. JAPAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. JAPAN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. INDIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. INDIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. INDIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. INDIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. INDIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. INDIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GERMANY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. GERMANY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. AUSTRALIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. AUSTRALIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AUSTRALIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AUSTRALIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AUSTRALIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. AUSTRALIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. SOUTH KOREA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. SOUTH KOREA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. SOUTH KOREA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. SOUTH KOREA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. SOUTH KOREA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. SOUTH KOREA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. RUSSIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. RUSSIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. RUSSIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. RUSSIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. RUSSIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. RUSSIA PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. SPAIN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. SPAIN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. SPAIN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. SPAIN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY STONE SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN PERCUTANEOUS NEPHROLITHOTOMY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 243. GLOBAL PERCUTANEOUS NEPHROLITHOTOMY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025